Autopsy studies involving patients with cancer and leukemia patients in remission of their leukemia to repetitive periods of ú30 days of absolute neutropenia [6 -8] ; this policy increases have demonstrated an increase in the incidence of invasive the likelihood that patients will present to transplantation with fungal infections over the past decade [1, 2] . A number of a history of an invasive fungal infection during one of the developments contribute to this trend. First, successful antibacprevious episodes of neutropenia. terial chemotherapy has reduced the morbidity and mortality A recent survey involving 120 patients with invasive asperdue to bacterial infections during neutropenia, thus increasing gillosis (IA) demonstrated that IA in patients with hematologic the risk for fungal colonization [3 -5] . Second, intensification malignancies represents a considerable therapeutic challenge, of chemotherapy has resulted in prolonged neutropenia and with a mortality rate solely attributable to IA of 40% at 3 more extensive disruption of mucosal barriers, especially in months after diagnosis [9, 10] . Secondary prophylaxis for repatients with leukemia. Currently, induction treatment of leukelapse of invasive fungal infection in patients undergoing bone mia is directed toward prognostic risk factors such as cytogemarrow transplantation (BMT) is therefore becoming an issue netics and response to initial treatment. A higher number of of real concern. Azole antifungals are effective against candidal patients receive intensification of treatment with high doses of infection and other yeast infections [11, 12] . For mold infeccytosine arabinoside as a result of this strategy. Intensification tions like those due to Aspergillus and Fusarium, little data are of treatment with high doses of cytosine arabinoside exposes available on the effectiveness of prophylaxis [11, 13] Of the 48 patients in this retrospective study, 19 were normally sterile body fluid that was obtained in a sterile fashion women, and 29 were men; the patients' ages ranged from 1 to showed septate hyphae microscopically or Aspergillus species 59 years (median, 33 years). Underlying hematologic diseases in culture; probable -invasive pulmonary disease and the presincluded acute myeloid leukemia in 34 patients, acute lymphoence of clinical signs and symptoms together with a cavitary cytic leukemia in 9, severe aplastic anemia in 4, and chronic lesion on a roentgenogram with a halo sign on a CT or the myeloid leukemia in 1. The time between diagnosis of the presence of suggestive radiological findings with positive reunderlying disease and the onset of IA ranged from 14 days sults of cytological examination or culture of a bronchoalveolar to 72 months (median, 3 months). Documented IA was found lavage (BAL) fluid specimen; and relapse -in the same fashion in 10 patients, and probable IA occurred in 38. The disease as documented or probable cases, but time to relapse was originated in the lungs in 44 patients and in the sinus in four. counted as the first day of radiological suspicion not that of A blood culture was positive for one patient with aspergillosis. the repeated culture or biopsy examination.
There were no patients with CNS infections due to Aspergillus as part of their primary episode of IA.
Data Collection
Information collected was divided into data on the pretrans-
Treatment of Primary IA
plantation episode of IA, data on transplantation, and data on relapse IA and total mortality. All patients received antifungal drugs as treatment for their initial episode of IA. Four patients received itraconazole only, Pretransplantation data included age; sex; underlying disease; time from underlying disease to pretransplantation diag-4 received itraconazole and amphotericin B, 34 received amphotericin B at a dosage of at least 0.7 mg/(kgrd), and 10 nosis of IA; localization and documentation of IA; medical, surgical, and growth factor treatment of the initial episode received liposomal amphotericin B (AmBisome, Vestar, San Dimas, CA). For two patients, 5-fluorocytosine was added to of IA; and clinical, radiological, and mycological response to treatment of the initial episode of IA.
the amphotericin B treatment.
/ 9c4c$$my08 04-17-98 15:00:25 cida UC: CID to be positive for four. All four patients had severe aplastic None 15 (31) anemia; further delay of transplantation was judged to be detri- Cyclosporine/MTX 22 (46) mental to the outcome for these patients. The interval between clinical resolution of primary IA and BMT ranged from persistent positive cultures at the time of transplantation to 21 months (median, 3 months). The characregimen (busulfan/cyclophosphamide or other regimen), T cell teristics of the 48 patients, including transplant donor, manipudepletion (yes or no), cyclosporine as part of the immunosuplation of the graft, conditioning regimen, TBI, immunosupprespressive treatment (yes or no), prophylaxis with itraconazole sive therapy, and incidence of GVHD that eventually required after BMT (yes or no), intravenous amphotericin B (yes or no), steroid treatment, are summarized in table 1. treatment with liposomal amphotericin B (yes or no), The median time to recovery of the granulocyte count to and growth factor treatment (granulocyte or granulocyte-100, 500, and 1,000/mL was 16 days (range, 6 -50 days), 21 macrophage CSF or none). The multivariate analysis demondays (range, 7 -61 days), and 24 days (range, 19 -319 days), strated that none of the risk factors had a statistically significant respectively. Six patients died before the count ever reached effect on relapse IA, total mortality, and IA-related mortality 100/mL. Platelet transfusions were stopped at a median of 36 with one exception: rates of total mortality (P Å .02) and IAdays (range, 8 -150 days); 12 patients died before transfusions related mortality (P Å .01) were significantly lower among were stopped. busulfan/cyclophosphamide -treated patients than among those receiving other conditioning regimens.
Relapse IA and Survival
The risk factors to be analyzed were determined from a
Influence of Neutropenia and GVHD
clinical viewpoint with emphasis on factors subject to clinical decision, such as pretransplantation surgery, choice of antifunDuration of neutropenia and GVHD and its treatment with corticosteroids are widely believed to be important risk factors gal prophylaxis, type of immunosuppressive treatment, and graft manipulation (T cell depletion). The following dichotofor relapse IA. These variables were analyzed separately for two reasons: first, patients who died before recovery of the mous risk factors were analyzed by multiple logistic regression: surgical treatment of initial IA (yes or no), clinical resolution granulocyte count would introduce a bias by skewing the data on the risk of mortality, and second, they are variables that do not of IA by the time of transplantation (yes or no), donor type (autologous, allomatched sibling, mismatched sibling, or unreplay a role in clinical decisions on the planning of transplantation because their outcome is unpredictable at that time. No statistical lated matched or mismatched), TBI (yes or no), conditioning / 9c4c$$my08 04-17-98 15:00:25 cida UC: CID trast to only 12 (29%) of 41 patients receiving intraconazole 16-25 20 6 10 or some formulation of intravenous amphotericin B therapy. 6 months) after BMT. Total survival and differences in survival rates between patients with relapse IA and those without relapse IA are shown significance was found by univariate analysis with Fisher's exact by Kaplan-Meier curves in figure 1 . IA was implicated as a test on ordinal groups for recovery of the granulocyte count to contributing cause of death in all 14 of the 16 patients with 100/mL and 500/mL and on dichotomous groups for the presence relapse IA who died. Two patients with acute myeloid leukemia of GVHD (less than grade 2 vs. grade 2 or higher) and treatment and relapse IA recovered: one had probable lung disease folof GVHD (steroids vs. none) (table 2). lowing autologous BMT that was treated with liposomal amphotericin B, and one had lung disease and a documented giant
Secondary Antifungal Prophylaxis
brain abscess following matched allogeneic BMT. The brain Forty-one of the 48 patients were receiving secondary proabscess became encapsulated following discontinuation of imphylaxis. Secondary prophylaxis consisted of intravenous amphotericin B only in 16 patients, itraconazole only in 6, and liposomal amphotericin B only in 6. Thirteen patients received more than one drug: intravenous amphotericin B and itraconazole for 9, liposomal amphotericin B only after amphotericin B for 1, and itraconazole plus conventional amphotericin B switched to itraconazole plus liposomal amphotericin B on the day of transplantation for 3. The dosage of itraconazole was 200 mg/d for 5 patients, 400 mg/d for 11, and 600 mg/d for 2. There was a wide variation in daily doses of conventional amphotericin B (0.25 to 1.5 mg/[kgrd]; median, 0.5 mg/[kgrd]). Cumulative doses ranged from 105 to 4,900 mg given over 7 to 71 days. Liposomal amphotericin B was given at doses ranging from 0.5 to 5 mg/(kgrd) (median, 1.5 mg/[kgrd]). Cumulative doses ranged from 750 to 16,000 mg (median, 2,400 mg) given over 10 to 80 days. abnormalities do not necessarily imply persistent infection or that IA is a multifocal disease on the microscopic level and that Discussion absence of lesion does not imply cure. Since this was a multicenter study with a limited number of patients who underwent surThis retrospective study of the incidence and clinical course of relapse IA following BMT in patients with previous IA was gery, considerable variability in surgical approach may have been present and has not been taken into account. For example, the initiated as an EBMT-EORTC joint project for two reasons. First, there was an almost total absence of data and guidelines statistical approach used does not allow for a difference between patients who have never had more than focal disease and patients on the ethical acceptability of BMT despite the increasing frequency of IA, which is associated with a high mortality rate.
in whom a residual focus was resected after medical treatment of multifocal disease. This may explain why there is a discrepancy in Second, the poor performance of available drugs and the high risk of relapse IA required assessment of the magnitude of this the results obtained with surgery in previous reports [15] [16] [17] [18] and the apparent lack of statistical significance of surgical intervention risk and investigation of associated risk factors in planning trials of new promising antifungal treatments for patients unemerging from this analysis. Conditioning with busulfan/cyclophosphamide was the only dergoing BMT. In 1993, an initial questionnaire was circulated to 75 BMT centers to solicit opinions on whether IA should factor that was associated with lower overall mortality and lower IA-related mortality. In the univariate analysis, a transbe considered a contraindication to BMT and, if not, how it should be managed [14] . Sixteen centers agreed to participate plant from an unrelated or mismatched donor had an adverse effect, but this circumstance was not a separate risk factor in in data collection from cases of patients who had undergone BMT following a history of IA; these data resulted in the the multivariate analysis (data not shown). This study included predominantly patients with pulmonary IA; it may be expected present analysis.
In our survey, relapse IA was documented in 16 (33%) of therefore that radiation to the lungs during TBI would make patients more susceptible to relapse IA than after conditioning 48 patients. However, when it occurred, it was fatal in 14 (88%) of 16 patients, usually despite aggressive treatment. This with busulfan/cyclophosphamide. TBI however was not a separate risk factor in either the univariate analysis or the multivarilower-than-expected incidence of relapse IA may be interpreted in different ways.
ate analysis. The observations that conditioning with busulfan/ cyclophosphamide is associated with lower mortality and that On the one hand, before transplantation, the number of patients with documented IA was low (21%) compared with the conditioning with TBI is not associated with higher mortality may therefore appear contradictory. These apparently contranumber of patients with probable IA (79%). Indeed, relapse IA occurred more frequently in patients with documented IA dictory observations may be explained by the presence of patients with severe aplastic anemia who underwent trans-(five of 10 patients) than in patients with probable IA (11 of 38 patients). The definition of probable IA remains however plantation with persistent IA after conditioning with cyclophosphamide/antithymocyte globulin and therefore without TBI. sufficiently stringent that the practicing physician confronted with this situation cannot afford not to treat it. On the other This group contributes to an adverse prognosis for the patients who did not undergo TBI but not for those receiving busulfan/ hand, the interval between the primary episode of IA and transplantation was usually sufficiently long to allow for complete cyclophosphamide conditioning.
Other variables expected to be of importance such as duraclinical resolution, with the notable exception of the four patients with aplastic anemia who underwent transplantation detion of neutropenia [3, 6] and the type of immunosuppressive prophylaxis [17] did not affect relapse IA, total mortality, or spite persistent IA and uniformly fared badly. Finally, although all of the 48 patients met the criteria of the definition of IA, IA-related mortality. The influence of GVHD and its treatment is difficult to assess in this study. Although the cumulative only one (for whom a blood culture was positive) had truly disseminated disease. The other patients had invasive localized incidence of grade 2 or higher GVHD was 43% (16 of 37 allomatched bone marrow patients), it was confined to skin disease. The results of this study should not be extrapolated to patients with primary disseminated IA, including CNS localizainvolvement in almost all cases, and all patients were treated with standard corticosteroid dosages of 2 mg/(kgrd). tion.
The relatively long interval that enables recovery certainly The administration of prophylactic growth factors was not significantly related to a lower risk of relapse, but there was a introduces a bias toward the inclusion of only those patients whose prognosis with respect to relapse of malignancy is better consistent trend toward lower rates of relapse IA, total mortality, and IA-related mortality. In view of the relatively small than if the interval between primary IA and BMT were shorter. This bias is reflected in the relatively low overall mortality rate impact that may be expected on the basis of current data [18] , the lack of finding statistical significance may well be due to (48%), which is similar to the average mortality rate among bone marrow transplant patients who have not had IA before the low number of patients (only 11) who were treated with growth factors. transplantation.
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